Drug-Eluting Stents More Dollars Than Sense?

被引：2

作者：

Garg, Sunil ^{[1
,2
]}

Eisenberg, Mark J. ^{[2
,3
,4
]}

机构：

[1] McGill Univ, Div Cardiol, Ctr Hlth, Montreal, PQ H3T 1E2, Canada

[2] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Jewish Gen Hosp, Montreal, PQ H3T 1E2, Canada

[3] McGill Univ, Div Cardiol, Jewish Gen Hosp, Montreal, PQ H3T 1E2, Canada

[4] McGill Univ, Div Clin Epidemiol, Jewish Gen Hosp, Montreal, PQ H3T 1E2, Canada

来源：

JACC-CARDIOVASCULAR INTERVENTIONS | 2009年 / 2卷 / 12期

关键词：

cost-effectiveness; drug-eluting stents; target vessel revascularization; QALY; quality-adjusted life year; CORONARY-ARTERY LESIONS; COST-EFFECTIVENESS; TRIAL;

D O I：

10.1016/j.jcin.2009.11.001

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The clinical and economic analysis by Eisenstein et al. (1) in this issue of JACC- Cardiovascular Interventions is a welcome addition to the collective literature on the cost-effectiveness of drug-eluting stents (DES). There are limited trial data regarding this topic, and most appraisals have been based on registry assessments. Eisenstein et al. (1) present the long-term clinical and economic analysis of a trial comparing a DES (zotarolimus, Endeavor, Medtronic CardioVascular, Santa Rosa, California) versus a bare-metal stent (BMS) (Driver, Medtronic CardioVascular). The Inclusion of data up to 4 years post-index procedure is particularly important given concerns with late stent thrombosis with DES.

引用

收藏

页码：1188 / 1189

页数：2

相关论文

共 6 条

[1] A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents [J].

Babapulle, MN ;

Joseph, L ;

Bélisle, P ;

Brophy, JM ;

Eisenberg, MJ .

LANCET, 2004, 364 (9434) :583-591

[2] Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization - Results from the TAXUS-IV trial [J].

Bakhai, Ameet ;

Stone, Gregg W. ;

Mahoney, Elizabeth ;

Lavelle, Tara A. ;

Shi, Chunxue ;

Berezin, Ronna H. ;

Lahue, Betsy J. ;

Clark, Mary Ann ;

Lacey, Michael J. ;

Russell, Mary E. ;

Ellis, Stephen G. ;

Hermiller, James B. ;

Cox, David A. ;

Cohen, David J. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 48 (02) :253-261

[3] Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses - Results from the sirolimus-eluting balloon expandable stent in the treatment of patients with de novo native coronary artery lesions (SIRIUS) trial [J].

Cohen, DJ ;

Bakhai, A ;

Shi, CX ;

Githiora, L ;

Lavelle, T ;

Berezin, RH ;

Leon, MB ;

Moses, JW ;

Carrozza, JP ;

Zidar, JP ;

Kuntz, RE .

CIRCULATION, 2004, 110 (05) :508-514

[4] Long-Term Clinical and Economic Analysis of the Endeavor Drug-Eluting Stent Versus the Driver Bare-Metal Stent 4-Year Results From the ENDEAVOR II Trial (Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions) [J].

Eisenstein, Eric L. ;

Wijns, William ;

Fajadet, Jean ;

Mauri, Laura ;

Edwards, Rex ;

Cowper, Patricia A. ;

Kong, David F. ;

Anstrom, Kevin J. .

JACC-CARDIOVASCULAR INTERVENTIONS, 2009, 2 (12) :1178-1187

[5] Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine encapsulated stent for treatment of native coronary artery lesions:: Clinical and angiographic results of the ENDEAVOR II trial [J].

Fajadet, Jean ;

Wijns, William ;

Laarman, Gert-Jan ;

Kuck, Karl-Heinz ;

Ormiston, John ;

Munzel, Thomas ;

Popma, Jeffrey J. ;

Fitzgerald, Peter J. ;

Bonan, Raoul ;

Kuntz, Richard E. .

CIRCULATION, 2006, 114 (08) :798-806

[6] Cost-Effectiveness of Drug-Eluting Stents Including the Economic Impact of Late Stent Thrombosis [J].

Filion, Kristian B. ;

Roy, Arup Michael ;

Baboushkin, Tara ;

Rinfret, Stephane ;

Eisenberg, Mark J. .

AMERICAN JOURNAL OF CARDIOLOGY, 2009, 103 (03) :338-344